Every 10-Q that Nurix Therapeutics, Inc. (NRIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NRIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRIX filings page.
Nurix Therapeutics reported another period of heavy investment as it advances its protein degradation pipeline, with a net loss of $176.7 million for the six months ended May 31, 2026, compared with $99.8 million a year earlier.
Total revenue fell to $15.3 million from $62.5 million, mainly due to the absence of prior-period license revenue, while research and development spending rose to $171.8 million as clinical programs for bexobrutideg, zelebrudomide and NX‑1607 progressed.
The company ended the quarter with $443.5 million in cash, cash equivalents and marketable securities and 103.7 million shares outstanding. After quarter‑end, Nurix signed a global collaboration with Roche for bexobrutideg, including a $700 million upfront payment and potential milestones bringing total payments up to $2.3 billion.
Nurix Therapeutics, Inc. reported higher losses for the quarter ended February 28, 2026 as it invested heavily in its targeted protein degradation pipeline. Collaboration revenue fell to $6.3 million from $18.5 million a year earlier, mainly reflecting timing of milestone and research activities.
Research and development expenses rose to $84.1 million from $69.7 million, driving a net loss of $87.2 million versus $56.4 million in the prior-year quarter. Operating cash outflow was $71.9 million, while cash, cash equivalents and marketable securities totaled $540.7 million, which management believes is sufficient for at least 12 months of operations.
The company continues to advance clinical programs including BTK degraders bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127), and CBL‑B inhibitor NX‑1607. It maintains sizable collaboration potential with Gilead, Sanofi and Pfizer and access to equity financing through at-the-market and registered direct offerings.
Nurix Therapeutics (NRIX) is a clinical-stage company focused on targeted protein degradation with partnered discovery programs and wholly owned BTK and CBL-B programs. For the nine months ended August 31, 2025 the company reported a net loss of $186.2M and an accumulated deficit of $925.0M. Cash, cash equivalents and marketable securities were $428.8M, which management expects is sufficient to fund operations for at least the next 12 months.
Collaboration and license activity remain a primary source of revenue: license revenue of $30.0M was recognized in the nine months ended August 31, 2025, and deferred revenue balances were $5.5M (Gilead), $35.7M (Pfizer) and $0 (Sanofi) as of August 31, 2025. The company expects substantial additional funding will be required beyond 12 months to complete clinical development and commercialization efforts and may pursue equity, debt or partnership financing.